EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy of additional ExTRa Mapping‐guided substrate ablation beyond pulmonary vein isolation in persistent atrial fibrillation: The ROTATE trial

Tetsuma Kawaji iD, Takanori Aizawa, Satoshi Shizuta iD, Saki Yamano, Misaki Naka, Bingyuan Bao, Shun Hojo, Shintaro Matsuda, Masashi Kato, Takafumi Yokomatsu iD, Shinji Miki

Journal of Cardiovascular Electrophysiology · 2025-08 · 36 (8) · 1999-2010

DOI: 10.1111/jce.16772 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 23.06.2025. Verfasst von Tetsuma Kawaji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation, Electrophysiologic Techniques, Cardiac. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There are currently no established effective additional substrate ablation strategies beyond pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF).

Objective

This randomized clinical trial evaluated the efficacy of a novel substrate ablation technique using the ExTRa Mapping system, which visualizes rotational activation during AF rhythm.

Methods

This study included 80 patients undergoing initial catheter ablation for persistent AF. Eighty patients whose AF persisted after PVI and ExTRa Mapping were randomly assigned in a 1:1 ratio to either PVI alone or PVI plus ExTRa Mapping‐guided substrate ablation targeting areas with high non‐passively activated ratio(%NP)( ≥ 35%)(ExTRa group). The primary outcome measure was recurrence of atrial tachyarrhythmias after a 90‐day blanking period postablation.

Results

Post‐PVI ExTRa Mapping assessed a median of 36 sites per patient in both atria. Baseline characteristics were comparable between groups. The ExTRa group showed higher event‐free survival from the primary outcome compared to the PVI alone group (85.0% vs . 67.5% at 1‐year, p = 0.07). This favorable prognosis was more pronounced for patients with a large( ≥ 12 sites) area of rotational activation area (81.0% vs. 57.9% at 1‐year, p = 0.01). Multivariable analysis identified the number of high %NP areas as an independent risk factor for recurrent tachyarrhythmias (HR 1.13, 95%CI 1.03–1.23, p = 0.005), while ExTRa Mapping‐guided substrate ablation emerged as a unique protective factor (HR 0.38, 95%CI 0.13‐0.99, p = 0.047).

Conclusion

While the reduction in atrial tachyarrhythmia recurrence of persistent AF patients did not reach statistical significance, the addition of ExTRa Mapping™‐guided substrate ablation beyond PVI demonstrated promising potential, especially in patients with larger rotational activation areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPulmonary VeinsCatheter AblationElectrophysiologic Techniques, CardiacHumansMaleFemaleMiddle AgedAgedHeart RateAction PotentialsRecurrenceTime FactorsRisk FactorsPredictive Value of TestsTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

ExTRa mappingatrial fibrillationatrial fibrillation drivercatheter ablationpersistent atrial fibrillation

Autor:innen und Institutionen

  • Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto.

ORCID-Profile: Tetsuma Kawaji, Satoshi Shizuta, Takafumi Yokomatsu

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Kawaji, T., Aizawa, T., Shizuta, S., Yamano, S., Naka, M., Bao, B., Hojo, S., Matsuda, S., Kato, M., Yokomatsu, T., & Miki, S. (2025). Efficacy of additional ExTRa Mapping‐guided substrate ablation beyond pulmonary vein isolation in persistent atrial fibrillation: The ROTATE trial. Journal of Cardiovascular Electrophysiology, 36(8), 1999-2010. https://doi.org/10.1111/jce.16772

Vancouver

Kawaji T, Aizawa T, Shizuta S, Yamano S, Naka M, Bao B, et al. Efficacy of additional ExTRa Mapping‐guided substrate ablation beyond pulmonary vein isolation in persistent atrial fibrillation: The ROTATE trial. Journal of Cardiovascular Electrophysiology. 2025;36(8):1999-2010. doi:10.1111/jce.16772

BibTeX
@article{Kawaji2025,
  author = {Kawaji, Tetsuma and Aizawa, Takanori and Shizuta, Satoshi and Yamano, Saki and Naka, Misaki and Bao, Bingyuan and Hojo, Shun and Matsuda, Shintaro and Kato, Masashi and Yokomatsu, Takafumi and Miki, Shinji},
  title = {Efficacy of additional ExTRa Mapping‐guided substrate ablation beyond pulmonary vein isolation in persistent atrial fibrillation: The ROTATE trial},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  volume = {36},
  number = {8},
  pages = {1999--2010},
  doi = {10.1111/jce.16772}
}
Kostenlos starten →